Skip to main content

Stephanie Holland

Conference Coverage
02/13/2025
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion...
02/13/2025
Oncology
Conference Coverage
02/13/2025
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3...
02/13/2025
Oncology
News
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
FDA Approval
02/11/2025
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase...
02/11/2025
Oncology
News
02/07/2025
Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.
Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.
Updated results from the phase 3...
02/07/2025
Oncology
News
02/05/2025
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the...
02/05/2025
Oncology
News
02/04/2025
According to results from the phase 1b/2 MORPHEUS-Liver trial, the addition of tiragolumab to atezolizumab plus bevacizumab demonstrated promise among patients with previously untreated locally advanced or unresectable hepatocellular...
According to results from the phase 1b/2 MORPHEUS-Liver trial, the addition of tiragolumab to atezolizumab plus bevacizumab demonstrated promise among patients with previously untreated locally advanced or unresectable hepatocellular...
According to results from the...
02/04/2025
Oncology
Conference Coverage
01/30/2025
According to results from the phase 3 ALTAIR study, trifluridine plus tipiracil provided a promising disease-free survival benefit for patients with resected oligometastatic colorectal cancer.
According to results from the phase 3 ALTAIR study, trifluridine plus tipiracil provided a promising disease-free survival benefit for patients with resected oligometastatic colorectal cancer.
According to results from the...
01/30/2025
Oncology
News
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology